Skip to content

Total Liabilities at other companies

Pfizer logo
PfizerPFE
$3.41B-97.1%
Incyte logo
IncyteINCY
$1.72B-17.6%
Amgen logo
AmgenAMGN
CG Oncology logo
CG OncologyCGON
Scholar Rock logo
Scholar RockSRRK
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s total liabilities?
Cogent Biosciences, Inc. (COGT) reported total liabilities of $295.31M in Q1 2026.
How has Cogent Biosciences, Inc.'s total liabilities changed year-over-year?
Cogent Biosciences, Inc.'s total liabilities increased by 355.7% year-over-year, from $64.8M to $295.31M.
What is the long-term trend for Cogent Biosciences, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s total liabilities has grown at a 79.3% compound annual growth rate (CAGR), from $16.25M to $301.24M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.